Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential
Source: SeekingAlpha
2025-09-02 09:14:49 ET
Investment Thesis
The first question I consider when I think of a company in molecular diagnostics is whether it can translate complex science into a commercially viable business.
A lot of companies develop tests that are really exciting, but they are unable to scale or have guaranteed reimbursement. The economics never actually work out without that....
Read the full article on Seeking Alpha
For further details see:
Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential
Castle Biosciences Inc.
NASDAQ: CSTL
CSTL Trading
1.08% G/L:
$25.32 Last:
82,523 Volume:
$25.40 Open:
CSTL Latest News
March 13, 2026 11:02:12 am
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
March 09, 2026 07:00:00 am
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
March 04, 2026 04:30:00 pm
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB
March 03, 2026 04:30:00 pm
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
CSTL Stock Data
$948,047,644
27,291,396
0.3%
60
N/A
Medical Diagnostics & Screening
Healthcare
US
Friendswood
